Tests ARGX-121 in adults with IgA nephropathy kidney disease
Tests ARGX-121 against placebo in adults with IgA nephropathy, a kidney disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Key facts
- Where
- Houston, Manassas, Miami, Pembroke Pines, Pontiac, Salt Lake City, and Valencia, United StatesSee the 9 sites
- Phase
- Phase 2
Where in United States
- Northwest Houston Arthritis Center - HoustonHouston, United StatesNot yet recruiting
- Prolato Clinical Research CenterHouston, United StatesTaking people
- Kidney and Hypertension Specialists- VirginiaManassas, United StatesTaking people
- Bioresearch PartnersMiami, United StatesTaking people
- Nephrology Associates of South Miami PAMiami, United StatesTaking people
- BioResearch Partner - Pembroke PinesPembroke Pines, United StatesTaking people
- Michigan Kidney ConsultantsPontiac, United StatesTaking people
- Utah Kidney Research InstituteSalt Lake City, United StatesTaking people
- Amicis Research Center - ValenciaValencia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- argenx
- Trial code
- NCT07773727EU 2026-525638-43-00
- Record updated
- 27 October 2026
- Original description
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise.
The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.
Inclusion: Males and females (not pregnant); At least 18 years old; Clinically diagnosed with IgAN with biopsy confirmation.
Exclusion: Recent Major surgery or organ transplant; Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of IgAN; History of Malignancy; Active infection of concern; Has secondary form of IgAN leading to IgA deposits.